OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study

被引:4
|
作者
Clemente, Lidia [1 ]
Cennamo, Gilda [2 ]
Montorio, Daniela [1 ]
Fossataro, Federica [1 ]
Passaro, Maria Laura [1 ]
Costagliola, Ciro [1 ]
机构
[1] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, Naples, Italy
[2] Univ Naples Federico II, Publ Hlth Dept, Eye Clin, Naples, Italy
关键词
central serous chorioretinopathy; OCTA; vessel density; photodynamic therapy; eplerenone; ANGIOGRAPHY;
D O I
10.1177/11206721221131129
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate retinal and choriocapillary vessel density (VD) changes in patients with chronic central serous chorioretinopathy (CSC) treated with half-fluence verteporfin photodynamic therapy (vPDT) or eplerenone, using optical coherence tomography angiography (OCTA). Methods Patients affected by CSC and treated with vPDT and eplerenone were retrospectively studied. At baseline and 3 months after each treatment, all patients underwent a complete ophthalmological examination, including an evaluation of best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), spectral-domain optical coherence tomography (SD-OCT) and OCTA. Results Forty-eight eyes of patients with CSC were analysed. Twenty-four eyes were placed in the vPDT group, and 24 eyes formed the eplerenone group. In both groups, OCTA showed a significant improvement in the VD of deep capillary plexus (DCP) and choriocapillaris (CC) after treatments with respect to baseline (p < 0.001), whereas the VD of superficial capillary plexus (SCP) did not show significant differences (p > 0.05). The PDT group demonstrated a statistically significant increase in the VD of DCP and CC with respect to the eplerenone group (DCP p = 0.012; CC p = 0.004). A statistically significant reduction with respect to baseline in subfoveal choroidal thickness (SFCT) (p = 0.001 for vPDT group; p = 0.001 for eplerenone group) and in central foveal thickness (CFT) (p = 0.001 for vPDT group; p = 0.001 for eplerenone group) was also found. The SFCT was significantly thinnest in the PDT group with respect to the eplerenone group (p = 0.021). Conclusion OCTA allowed us to study retinal and choriocapillary vascular changes in patients with CSC treated with vPDT and eplerenone.
引用
收藏
页码:1090 / 1096
页数:7
相关论文
共 50 条
  • [41] Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy
    Smretschnig, E.
    Hagen, S.
    Glittenberg, C.
    Ristl, R.
    Krebs, I.
    Binder, S.
    Ansari-Shahrezaei, S.
    EYE, 2016, 30 (06) : 805 - 811
  • [42] Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy
    Butler, Andrea L.
    Fung, Adrian T.
    Merkur, Andrew B.
    Albiani, David A.
    Forooghian, Farzin
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2012, 47 (01): : 42 - 44
  • [43] Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy
    Park, Dong-Geun
    Jeong, Seongyong
    Noh, Donghyoun
    Sagong, Min
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2021, 105 (06) : 844 - 849
  • [44] Optical coherence tomography angiography quantification of choriocapillaris blood-flow after half-fluence photodynamic therapy for chronic central serous chorioretinopathy
    Le, Hoang Mai
    Mrejen, Sarah
    Sibilia, Lise
    Cohen, Salomon Y.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2483 - 2490
  • [45] Optical coherence tomography angiography quantification of choriocapillaris blood-flow after half-fluence photodynamic therapy for chronic central serous chorioretinopathy
    Hoang Mai Le
    Sarah Mrejen
    Lise Sibilia
    Salomon Y. Cohen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2483 - 2490
  • [46] Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic Therapy
    Yanik, Ozge
    Batioglu, Figen
    Yalcindag, Nilufer
    Demirel, Sibel
    Ozmert, Emin
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2022, 52 (02): : 147 - 152
  • [47] Oral Eplerenone For The Management Of Chronic Central Serous Chorioretinopathy
    Singh, Rishi P.
    Sears, Jonathan
    Bedi, Rumneek
    Schachat, Andrew
    Kaiser, Peter K.
    Ehlers, Justis
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [48] Oral eplerenone for the management of chronic central serous chorioretinopathy
    Singh, Rishi P.
    Sears, Jonathan E.
    Bedi, Rumneek
    Schachat, Andrew P.
    Ehlers, Justis P.
    Kaiser, Peter K.
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2015, 8 (02) : 310 - 314
  • [49] Oral eplerenone for the management of chronic central serous chorioretinopathy
    Rishi P Singh
    Jonathan E Sears
    Rumneek Bedi
    Andrew P Schachat
    Justis P Ehlers
    Peter K Kaiser
    International Journal of Ophthalmology, 2015, (02) : 310 - 314
  • [50] Correction to: Optical coherence tomography angiography quantification of choriocapillaris blood-flow after half-fluence photodynamic therapy for chronic central serous chorioretinopathy
    Hoang Mai Le
    Sarah Mrejen
    Lise Sibilia
    Salomon Y. Cohen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2391 - 2391